Developer of rare-disease drugs gets $4.6M boost

05/17/2013 | American City Business Journals

A Series A funding round has brought in $4.6 million for Callidus Biopharma, a development-stage biotech firm specializing in rare-disease drugs. The Pennsylvania-based company plans to use the proceeds mainly to speed up preclinical development of its drug candidates for lysosomal storage disorders, including Pompe and Gaucher diseases. Money also will go toward the launch of the firm's proprietary protein-expression technology.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX